期刊文献+

SLC12A1基因在肾透明细胞癌中的表达及其对预后的影响

Expression of SLC12A1 gene in renal clear cell carcinoma and its significance for prognosis
原文传递
导出
摘要 目的挖掘TCCA数据库中SLC12A1在肾透明细胞癌中的表达及其对预后的影响。方法首先利用TCGA可视化工具进行单因素方差分析比较SLCI2A1 mRNA在肾透明细胞癌组织(523例)和正常肾脏组织(100例)的表达差异,以及肾透明细胞癌不同临床分期的SLC12A1 mRNA的表达差异。以肾透明细胞癌样本的平均SLC12A1 mRNA的表达量为界限,将含有生存资料的509例肾透明细胞癌样本分为高表达组(252例)和低表达组(257例)。生存分析比较高表达组与低表达组总生存率和无事件生存率的差异。结果:SLC12A1 mRNA在肾透明细胞癌组织中的表达量低于正常肾脏组织(P<0.01)。且SLC12A1在Ⅰ期的平均表达量较Ⅱ-Ⅳ期高(P<0.01)。高表达组的总生存期较低表达组的高(P=0.037),而两组的无事件生存率比较,差异无统计学意义(P=0.053)。结论SLC12A1在肾透明细胞癌中高表达,Ⅰ期表达最高。SLC12A1在肾透明细胞癌不同分期中的表达差异与肾透明细胞癌预后有相关性。SLC12A1可能参与了肾透明细胞癌恶性程度的分子机制并指导肾透明细胞癌的诊断和治疗。 Objective To explore the expression of SLC12A1 in renal clear cell carcinoma and its impact on prognosis in TCGA database using bioinformatics methods.Methods The TCGA vi-sualization tool was used to compare the expression difference of SLC12A1 mRNA in renal clear cell carcinoma tissues(523 cases)and corresponding normal tissues(100 cases)and the expression difference of SLC12A1 mRNA in diferent clinical stages of renal clear cell carcinoma.Fnally,ac~cording to the expression level of SLC12A1 mRNA,50%(252 cases)with the highest expression lev-el and 50%(257 cases)with the lowest expression level were recorded as high expression group and low expression group,respectively.Survival analysis was higher than high expression group and low.The difference between the overall survival rate and the event-free survival rate in the expression group.Results The expression of SLC12A1 mRNA in renal clear cell carcinoma was significantly higher than that in normal tissues(P<0.01).The average expression level of SLC12A1 in stage Ⅰ was higher than that in stage Ⅱ-Ⅳ(P<0.01).Among 523 patients with renal clear cell carcinoma,the overall survival of the high-expression group was lower than that of the lower expression(P=:0.037),and there was no significant difference in the event free survival rate(P=0.053).Conclu-sions SLC12A1 is highly expressed in renal clear cell carcinoma,and the SLC12A1 mRNA in differ-ent clinical stages is statistically different,with the highest stage Ⅰ.The overall survival of the high expression group is lower in the expression group,and the difference is statistically significant.AI-though the diference between the event-free survival rate and the low-expression group in the high-ex-pression group is not statistically sigificant,it is suggested that the high-expression group have a high-er event-free survival group than the lower expression group.
作者 林联拯 李金雨 赵力 于忠英 张汉荣 庄园丽 Lin Lianzheng;Li Jinyu;Zhao Li;Yu Zhongying;Zhang Hanrong;Zhuang Yuanli(Department of Urology,Urinary Surgery of Hospital 909,Joint Logistic Support Force of PLA(Southeast Hospital,Xiamen University),Zhangzhou 363000,China)
机构地区 解放军
出处 《国际泌尿系统杂志》 2021年第3期444-446,共3页 International Journal of Urology and Nephrology
关键词 肾肿瘤 SLC12A1 膜蛋白质类 Kidney Neoplasms SLCI2AI Membrane Proteins
  • 相关文献

参考文献1

二级参考文献18

  • 1张骞,金杰,陶谦.抑癌基因甲基化在肾细胞癌研究中的新进展[J].癌症,2007,26(11):1276-1280. 被引量:16
  • 2MULDERS PF,BROUWERS AH,HULSBERGEN-VAN DER KAA CA,et al.Guideline ‘Renal cell carcinoma’[J].Ned Tijdschr Geneeskd.2008,152(7):376-380.
  • 3RINI BI,RATHMELL WK,GODLEY P.Renal cell carcinoma[J].Curr Opin Oncol,2008,20(3):300-306.
  • 4NI D,MA X,LI HZ,et al.Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma[J].Clin Cancer Res,2014,31.[Epub ahead of print].
  • 5XIA QY,RAO Q,CHENG L,et al.Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma[J].Histopathology,2013,26.[Epub ahead of print].
  • 6CAO L,ZHU L,YANG J,et al.Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma,gastric cancer and renal cell carcinoma[J].Int J Oncol,2014,44(4):1207-1214.
  • 7NI S,HU J,DUAN Y,et al.Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer[J].Cancer Sci,2013,104(7):817-825.
  • 8HAAS M.The Na-K-Cl cotransporters[J].Am J Physiol,1994,267(4 Pt1):C869-885.
  • 9MARKADIEU N,DELPIRE E.Physiology and pathophysiology of SLC12A1/2 transporters[J].Pflugers Arch,2014,466(1):91-105.
  • 10CARMOSINO M,PROCINO G,SVELTO M.Na+-K+-2Cl- cotransporter type 2 trafficking and activity: the role of interacting proteins[J].Biol Cell,2012,104(4):201-212.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部